|1.||Rosenblum, Michael G: 11 articles (02/2013 - 03/2004)|
|2.||Yang, Victor C: 6 articles (08/2015 - 09/2005)|
|3.||Mohamedali, Khalid A: 6 articles (01/2012 - 05/2005)|
|4.||Berg, K: 5 articles (06/2005 - 07/2000)|
|5.||Zhang, Jian: 4 articles (08/2015 - 11/2013)|
|6.||Shin, Meong Cheol: 4 articles (08/2015 - 11/2013)|
|7.||Min, Kyoung Ah: 4 articles (08/2015 - 11/2013)|
|8.||Huang, Yongzhuo: 3 articles (08/2015 - 11/2008)|
|9.||Trommer, Wolfgang E: 3 articles (12/2014 - 03/2006)|
|10.||Berg, Kristian: 3 articles (12/2013 - 03/2010)|
12/01/2015 - "The purpose of this study is to evaluate the early response of tumors to a vascular-disrupting agent (VDA) VEGF121/recombinant toxin gelonin (rGel) using dynamic [(18)F]FPPRGD2 positron emission tomography (PET) and kinetic parameter estimation. "
11/28/2014 - "More importantly, efficacy studies also revealed that only the TAT-gelonin/T84.66-Hep complex yielded a significant inhibition of tumor growth (46%) without causing gelonin-induced systemic toxicity. "
01/01/2013 - "In this study, we have constructed a recombinant plasmid which contained a tumor-specific survivin promoter to drive phytotoxin gelonin (pSur-Gel). "
09/01/2005 - "In vivo studies further confirmed that LMWP could carry an impermeable gelonin across the tumor mass and subsequently inhibit the tumor growth. "
01/01/2015 - "Gelonin was efficiently expressed in SKOV3 cancer cells in vitro and in vivo using pGelonin incorporated with HPEI nanogels. "
|2.||Melanoma (Melanoma, Malignant)
02/01/1996 - "Human melanoma cells (A375-M) were grown in the presence of increasing amounts of ZME-gelonin and a clonal variant (A-375-ZR) was developed that was 100-fold resistant to ZME-gelonin compared to parental cells. "
05/01/1995 - "Using a murine model for a rapidly growing lethal metastatic human melanoma, treatment with ZME-gelonin resulted in a mean survival of 44 days, 213% increase in mean survival time compared with the saline treatment (14.2 +/- 2 day survival). "
03/01/1991 - "The ZME-gelonin conjugate was 10(6)-fold more active than gelonin itself in inhibiting the growth of log-phase human melanoma cells in culture. "
01/01/1991 - "The gelonin-14G2a immunotoxin was directly cytotoxic to human melanoma (A375-M and AAB-527) cells and was 1000-fold more active than native gelonin in inhibiting the growth of human melanoma cells in vitro. "
05/01/1995 - "In nude mice bearing well-developed human tumor A375 melanoma xenografts, administration of 125I-labeled ZME and ZME-gelonin resulted in tumor-to-blood ratios of 1.9 +/- 0.5 and 1.5 +/- 0.6 respectively by 72 h. "
|3.||Myeloid Leukemia (Leukemia, Myelocytic)
12/01/1994 - "Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias."
02/01/2013 - "We conducted a phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with relapsed, refractory myeloid leukemias. "
12/01/1994 - "Immunotoxins (IT) reactive with human myeloid leukemias were constructed by conjugating gelonin, a single-chain ribosome-inactivating protein, to murine and genetically engineered, humanized M195 antibodies via an N-succinimidyl-3-(2-pyridyl-dithio)-propionate linkage. "
|4.||Hodgkin Disease (Hodgkin's Disease)
07/01/1995 - "Among CD30 tumour cell lines, the Hodgkin's lymphoma L428 was also sensitive to gelonin delivered by bimAbs (IC50 6 x 10(-11) M), whereas the COLE Hodgkin's cell line and the T-ALL Jurkat were completely resistant to the toxic effect of gelonin and bimAbs. "
10/01/1995 - "Among CD25-CD30+ Hodgkin's lymphoma lines, which were resistant to targeting by anti-CD25/saporin BsmAb, one (L428) was sensitive to both gelonin and saporin delivered by anti-CD30 BsmAb. "
07/01/1995 - "These bimAbs enhanced gelonin toxicity (IC50 5 x 10(-8) M, in the absence of mAbs) against the CD30+ L540 Hodgkin's lymphoma cell line in a protein synthesis inhibition assay. "
10/01/1995 - "In this study, we compared the ability of different bispecific monoclonal antibodies (BsmAb) and immunotoxins to deliver the type 1 ribosome-inactivating proteins (RIP) saporin and gelonin through the CD25 or CD30 target molecules to Hodgkin's lymphoma cells. "
|5.||Malignant Fibrous Histiocytoma
|6.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|9.||monoclonal antibody M195
|1.||Photochemotherapy (Photodynamic Therapy)
|2.||Heterologous Transplantation (Xenotransplantation)
|5.||Drug Therapy (Chemotherapy)